Drug and Therapeutics Bulletin 1995;33:15-16; doi:10.1136/dtb.1995.33215
Copyright © 1995 by the BMJ Publishing Group Ltd.

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Search for Related Content PubMed PubMed Citation

Dornase alfa for cystic fibrosis

In patients with cystic fibrosis thick viscous secretions, colonised by bacteria, accumulate in the respiratory tract and cause airway obstruction and recurrent exacerbations of infection. Standard treatment includes physiotherapy and antibiotics. Dornase alfa (Pulmozyme – Genentech/Roche) has recently been licensed in the UK for the longterm treatment of patients with cystic fibrosis aged over 5 years who have a forced vital capacity (FVC) greater than 40% of predicted. The manufacturer claims that dornase alfa, the first drug of its kind, produces ‘an improvement of pulmonary function’ and ‘a reduction in days requiring administration of parenteral antibiotics’.

This article has been cited by other articles:

				C. E Milla Long term effects of aerosolised rhDNase on pulmonary disease progression in patients with cystic fibrosis Thorax, December 1, 1998; 53(12): 1014 - 1017. [Abstract] [Full Text]